Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT04231708

Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder

This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological stress (vs. placebo) alter behavior in non-treatment seeking individuals with opioid use disorder (OUD). Specific Aims are to (1) Evaluate how stress impacts domains of behavior including (1a) executive function and (1b) opioid-seeking behavior; and (2) Determine whether rTMS stimulation attenuates (2a) executive dysfunction, (2b) stress-reactivity, and (2c) opioid-seeking in individuals with OUD not receiving treatment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

21 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Tolan Park Medical Building

Detroit, Michigan, 48201, United States

About this study

This study will use a double-blind, 10Hz left dlPFC rTMS (vs. sham) and pharmacological stressor ([yohimbine + hydrocortisone] vs. placebo) within-subject, randomized crossover design. Each participant will complete 4 sessions (stressor vs. placebo, crossed with rTMS vs. sham), each separated by at least 1 week. Participants will complete these 4 (2x2 within subject) test conditions in randomized order: sham rTMS/placebo stress, sham rTMS/active stress, active rTMS/ placebo stress, and active rTMS/active stress.

The PI will perform randomization using a Latin Square and will assign participants to conditions and prepare medication (stressor or placebo) for each participant's sessions. The PI will keep others blinded and will not be involved in study assessments.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meet DSM-5 criteria for OUD;
  • Age 21-60 yr;
  • Right handed;
  • Males and non-pregnant/non-lactating females;
  • cognitively intact (total IQ score >80 on Shipley Institute of Living Scale);
  • Screening cardiovascular indices within ranges for safe use of the pharmacological stressor: resting HR 50-90 bpm, systolic BP 90-140 mmHg, and diastolic BP 50-90 mmHg;
  • Use alcohol and/or marijuana <3 times/week; each "time" should consist of <1 marijuana "joint" equivalent and <3 alcoholic drinks.

Exclusion criteria

  • Under influence of any substance during session;
  • Past 7-day use of illicit drugs other than opioids (except marijuana, which is legal in Michigan);
  • Urinalysis positive for cocaine metabolites, benzodiazepines, barbiturates, amphetamines or pregnancy;
  • Medical conditions prohibiting use of rTMS (e.g. seizure history; based on rTMS screening questionnaire);
  • Lifetime diagnosis of: psychotic disorder, bipolar disorder, generalized anxiety disorder, or obsessive compulsive disorder; major depression in the past 5 years; or potentially antisocial personality disorder (if the clinical psychologist judges such behaviors to be potentially disruptive or unsafe in our lab);
  • Past-year SUD other than OUD;
  • Acute/unstable illness: conditions making it unsafe for participation (e.g. neurological, cardiovascular, pulmonary, or systemic diseases);
  • Lactose intolerance (placebo dose);
  • Any prohibited medications: medications that lower seizure threshold, psychiatric medications, prescription pain medications, or blood pressure medications;
  • Chronic head or neck pain; and
  • Past-month participation in a research study.

Treatment and study plan

Yohimbine + Hydrocortisone

Drug

Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)

Active rTMS

Device

10Hz rTMS over the left dlPFC

Placebo

Drug

lactose (inside capsule)

sham rTMS

Device

inactive stimulation over the left dlPFC

Primary outcomes

  1. Color-Word Stroop Task

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    measures cognitive control in response to opioid-related words.

  2. Digit Span Task

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    measures verbal working memory. Participants are asked to repeat strings of numbers of increasing length, both forward and backward.

  3. Wisconsin Card Sorting Task

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    measures ability to shift set and assesses cognitive flexibility.

  4. Emotion Regulation Task

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    subjects rate the unpleasantness and arousal of different emotional pictures

  5. Positive and Negative Affect Schedule

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    subjects rate their positive and negative affect

  6. State-Trait Anxiety Inventory

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    subjects rate their level state anxiety

  7. Monetary Incentive Delay Task

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    Participants respond to a visual target that follows 2 different cues: incentive or non-incentive. No reward or punishment occurs on non-incentive trials. On incentive trials, participants must respond within a fixed amount of time. In the reward condition, responses within that time result in receiving the incentive , else nothing. In the punishment condition, the participant will lose money if they do not respond within the time limit

  8. Delay Discounting Task

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    Participants perform a brief (<1min) hypothetical version of the traditional monetary task with a 5-trial adjusting delay previously validated to rapidly assess discount rate

  9. Drug/Money Choice Task

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    participants choose hypothetically between a constant amount of their preferred opioid ($10 unit dose) or money ($2)

  10. Systolic blood pressure

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    millimeters mercury (mmHg)

  11. Diastolic blood pressure

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    millimeters mercury (mmHg)

  12. Heart rate

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    beats per minute

  13. Saliva cortisol level

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    measure of the activity of the HPA axis

  14. Saliva alpha-amylase level

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    indirect measure of adrenergic stimulation

  15. Serum prolactin level

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    indirect measure of dopamine stimulation

  16. Serum brain derived neurotrophic factor (BDNF) level

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    indirect measure of brain derived neurotrophic factor activation

  17. Relative electroencephalogram (EEG) gamma power

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    Prefrontal gamma (25-100 Hz) EEG power, relative to slow-wave EEG power, is a stress biomarker

Secondary outcomes

  1. Opioid craving

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    Desire for Drug Questionnaire total score; higher scores indicate greater craving

  2. Opioid agonist symptoms

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    Opiate-32 questionnaire agonist symptom total score; higher scores indicate greater opioid symptom severity

  3. Opioid withdrawal symptoms

    Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)

    Opiate-32 questionnaire withdrawal symptom total score; higher scores indicate greater withdrawal severity

Sponsors and collaborators

Lead sponsor

Wayne State University

Other

Registry information

Official study title

Effects of Pharmacological Stress and Repetitive Transcranial Magnetic Stimulation Interventions on Executive Function in Opioid Use Disorder

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jan 18, 2020
Registry last updated
Dec 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.